You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name16-Bromoepiandrosterone
Accession NumberDB05107
TypeSmall Molecule
GroupsInvestigational
Description16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.
Structure
Thumb
Synonyms
16alpha-bromoepiandrosterone
External Identifiers
  • HE-2000
  • HE2000
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ImmunitinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9735KA370S
CAS number28507-02-0
WeightAverage: 369.336
Monoisotopic: 368.135092819
Chemical FormulaC19H29BrO2
InChI KeyCWVMWSZEMZOUPC-JUAXIXHSSA-N
InChI
InChI=1S/C19H29BrO2/c1-18-7-5-12(21)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(20)17(19)22/h11-16,21H,3-10H2,1-2H3/t11-,12-,13+,14-,15-,16+,18-,19-/m0/s1
IUPAC Name
(1S,2S,5S,7S,10R,11S,13R,15S)-13-bromo-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-one
SMILES
[H][C@@]12C[C@@H](Br)C(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C
Pharmacology
IndicationInvestigated for use/treatment in cystic fibrosis, HIV infection, hepatitis (viral, B), and malaria.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionHE2000 interacts with certain enzymes, including G6PDH (glucose 6 phosphate dehydrogenase); these enzymes could be involved in the mechanism. Also, the compound is in the steroid hormone series, and involved in control mechanisms in our cells that are much more complex, interacting with receptors and therefore changing the biochemistry of cells. This compound may have many modes of action; we are trying to understand what they may be.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucose-6-phosphate 1-dehydrogenaseProteinunknownNot AvailableHumanP11413 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with 16-Bromoepiandrosterone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with 16-Bromoepiandrosterone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with 16-Bromoepiandrosterone.Approved
Aldesleukin16-Bromoepiandrosterone may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 16-Bromoepiandrosterone.Approved
AmiodaroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin B16-Bromoepiandrosterone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with 16-Bromoepiandrosterone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with 16-Bromoepiandrosterone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with 16-Bromoepiandrosterone.Approved, Investigational
AprepitantThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with 16-Bromoepiandrosterone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with 16-Bromoepiandrosterone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with 16-Bromoepiandrosterone.Approved, Investigational
BazedoxifeneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Bazedoxifene.Approved, Investigational
Bendroflumethiazide16-Bromoepiandrosterone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with 16-Bromoepiandrosterone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with 16-Bromoepiandrosterone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with 16-Bromoepiandrosterone.Investigational
Bismuth SubcitrateThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with 16-Bromoepiandrosterone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with 16-Bromoepiandrosterone.Investigational
Bumetanide16-Bromoepiandrosterone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with 16-Bromoepiandrosterone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with 16-Bromoepiandrosterone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with 16-Bromoepiandrosterone.Experimental
CDX-110The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with 16-Bromoepiandrosterone.Approved, Investigational
Ceritinib16-Bromoepiandrosterone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
Chlorothiazide16-Bromoepiandrosterone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Chlorotrianisene.Withdrawn
Chlorthalidone16-Bromoepiandrosterone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of 16-Bromoepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with 16-Bromoepiandrosterone.Approved
CobicistatThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of 16-Bromoepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of 16-Bromoepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with 16-Bromoepiandrosterone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with 16-Bromoepiandrosterone.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with 16-Bromoepiandrosterone.Investigational
DarunavirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with 16-Bromoepiandrosterone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
DienestrolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with 16-Bromoepiandrosterone.Approved
Dihydrotestosterone16-Bromoepiandrosterone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with 16-Bromoepiandrosterone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with 16-Bromoepiandrosterone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with 16-Bromoepiandrosterone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with 16-Bromoepiandrosterone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with 16-Bromoepiandrosterone.Approved
EstradiolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Estrone.Approved
Etacrynic acid16-Bromoepiandrosterone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with 16-Bromoepiandrosterone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with 16-Bromoepiandrosterone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with 16-Bromoepiandrosterone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with 16-Bromoepiandrosterone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with 16-Bromoepiandrosterone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with 16-Bromoepiandrosterone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with 16-Bromoepiandrosterone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with 16-Bromoepiandrosterone.Approved
FenthionThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with 16-Bromoepiandrosterone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with 16-Bromoepiandrosterone.Vet Approved
Fluoxymesterone16-Bromoepiandrosterone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with 16-Bromoepiandrosterone.Approved, Investigational
FosaprepitantThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Fosphenytoin.Approved
Furosemide16-Bromoepiandrosterone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with 16-Bromoepiandrosterone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with 16-Bromoepiandrosterone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with 16-Bromoepiandrosterone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 16-Bromoepiandrosterone.Approved, Investigational
Hydrochlorothiazide16-Bromoepiandrosterone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydroflumethiazide16-Bromoepiandrosterone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with 16-Bromoepiandrosterone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with 16-Bromoepiandrosterone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with 16-Bromoepiandrosterone.Approved
IdelalisibThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of 16-Bromoepiandrosterone.Approved
Indapamide16-Bromoepiandrosterone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with 16-Bromoepiandrosterone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with 16-Bromoepiandrosterone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with 16-Bromoepiandrosterone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with 16-Bromoepiandrosterone.Withdrawn
ItraconazoleThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with 16-Bromoepiandrosterone.Experimental
KetoconazoleThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with 16-Bromoepiandrosterone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with 16-Bromoepiandrosterone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with 16-Bromoepiandrosterone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with 16-Bromoepiandrosterone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with 16-Bromoepiandrosterone.Approved
LumacaftorThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with 16-Bromoepiandrosterone.Approved, Investigational
MagaldrateThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 16-Bromoepiandrosterone.Approved
Magnesium TrisilicateThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with 16-Bromoepiandrosterone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with 16-Bromoepiandrosterone.Approved
MefloquineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with 16-Bromoepiandrosterone.Approved
MestranolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with 16-Bromoepiandrosterone.Withdrawn
MethallenestrilThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Methanesulfonyl Fluoride.Investigational
Methyclothiazide16-Bromoepiandrosterone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyltestosterone16-Bromoepiandrosterone may increase the fluid retaining activities of Methyltestosterone.Approved
Metolazone16-Bromoepiandrosterone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of 16-Bromoepiandrosterone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Minaprine.Approved
MitotaneThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with 16-Bromoepiandrosterone.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 16-Bromoepiandrosterone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 16-Bromoepiandrosterone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with 16-Bromoepiandrosterone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with 16-Bromoepiandrosterone.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with 16-Bromoepiandrosterone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with 16-Bromoepiandrosterone.Investigational
NefazodoneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with 16-Bromoepiandrosterone.Approved
NevirapineThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with 16-Bromoepiandrosterone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with 16-Bromoepiandrosterone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with 16-Bromoepiandrosterone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with 16-Bromoepiandrosterone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with 16-Bromoepiandrosterone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with 16-Bromoepiandrosterone.Vet Approved
Oxandrolone16-Bromoepiandrosterone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 16-Bromoepiandrosterone.Approved
Oxymetholone16-Bromoepiandrosterone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 16-Bromoepiandrosterone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with 16-Bromoepiandrosterone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with 16-Bromoepiandrosterone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
PhenytoinThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with 16-Bromoepiandrosterone.Approved, Investigational
Piretanide16-Bromoepiandrosterone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with 16-Bromoepiandrosterone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with 16-Bromoepiandrosterone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Polyestradiol phosphate.Approved
Polythiazide16-Bromoepiandrosterone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with 16-Bromoepiandrosterone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with 16-Bromoepiandrosterone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Quinestrol.Approved
Quinethazone16-Bromoepiandrosterone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with 16-Bromoepiandrosterone.Experimental, Investigational
RifabutinThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with 16-Bromoepiandrosterone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rosoxacin.Approved
S EquolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with 16-Bromoepiandrosterone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with 16-Bromoepiandrosterone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with 16-Bromoepiandrosterone.Approved
SaquinavirThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with 16-Bromoepiandrosterone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with 16-Bromoepiandrosterone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with 16-Bromoepiandrosterone.Investigational
St. John's WortThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with St. John's Wort.Nutraceutical
Stanozolol16-Bromoepiandrosterone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with 16-Bromoepiandrosterone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with 16-Bromoepiandrosterone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with 16-Bromoepiandrosterone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with 16-Bromoepiandrosterone.Approved
TelithromycinThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with 16-Bromoepiandrosterone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with 16-Bromoepiandrosterone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with 16-Bromoepiandrosterone.Approved
Testosterone16-Bromoepiandrosterone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with 16-Bromoepiandrosterone.Approved
TiboloneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with 16-Bromoepiandrosterone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with 16-Bromoepiandrosterone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with 16-Bromoepiandrosterone.Approved
Torasemide16-Bromoepiandrosterone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with 16-Bromoepiandrosterone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Trichlorfon.Vet Approved
Trichlormethiazide16-Bromoepiandrosterone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with 16-Bromoepiandrosterone.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with 16-Bromoepiandrosterone.Investigational, Withdrawn
VoriconazoleThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Voriconazole.Approved, Investigational
Warfarin16-Bromoepiandrosterone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with 16-Bromoepiandrosterone.Approved
ZeranolThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with 16-Bromoepiandrosterone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with 16-Bromoepiandrosterone.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Frincke JM, Stickney DR, Onizuka-Handa N, Garsd A, Reading C, Krudsood S, Wilairatana P, Looareesuwan S: Reduction of parasite levels in patients with uncomplicated malaria by treatment with HE2000. Am J Trop Med Hyg. 2007 Feb;76(2):232-6. [PubMed:17297029 ]
  2. Reading C, Dowding C, Schramm B, Garsd A, Onizuka-Handa N, Stickney D, Frincke J: Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000). Clin Microbiol Infect. 2006 Nov;12(11):1082-8. [PubMed:17002607 ]
  3. Frincke J: HE2000 begins clinical trials: interview with James Frincke, Ph.D. Interview by John S. James. AIDS Treat News. 1999 Jun 4;(No 320):4-7. [PubMed:11366467 ]
  4. Authors unspecified: HE2000 corrects immune system dysregulation in HIV-positive patients. AIDS Read. 2000 May;10(5):282. [PubMed:10851716 ]
  5. Authors unspecified: HE2000 shows efficacy. AIDS Patient Care STDS. 1999 Jun;13(6):375. [PubMed:10842861 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9825
Caco-2 permeable+0.8006
P-glycoprotein substrateSubstrate0.5669
P-glycoprotein inhibitor INon-inhibitor0.6611
P-glycoprotein inhibitor IINon-inhibitor0.7795
Renal organic cation transporterNon-inhibitor0.7902
CYP450 2C9 substrateNon-substrate0.8133
CYP450 2D6 substrateNon-substrate0.8886
CYP450 3A4 substrateSubstrate0.7282
CYP450 1A2 substrateNon-inhibitor0.7876
CYP450 2C9 inhibitorNon-inhibitor0.7726
CYP450 2D6 inhibitorNon-inhibitor0.938
CYP450 2C19 inhibitorNon-inhibitor0.9056
CYP450 3A4 inhibitorNon-inhibitor0.7977
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9292
Ames testNon AMES toxic0.8898
CarcinogenicityNon-carcinogens0.9022
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.2317 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9501
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00209 mg/mLALOGPS
logP4.45ALOGPS
logP4.44ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)17.86ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity91.34 m3·mol-1ChemAxon
Polarizability37.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
Substituents
  • Androgen-skeleton
  • 3-beta-hydroxysteroid
  • Oxosteroid
  • 17-oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 16-halo-steroid
  • 3-hydroxysteroid
  • Cyclic alcohol
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl bromide
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis.
Gene Name:
G6PD
Uniprot ID:
P11413
Molecular Weight:
59256.31 Da
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24